PFIZER/EISAI ARICEPT PHARMACOECONOMIC ANALYSIS WILL BE READY BY JANUARY LAUNCH; ALZHEIMER'S DRUG HAS ONCE-DAILY DOSING AND NO LIVER ENZYME ELEVATIONS
Executive Summary
Aricept cost-effectiveness outcomes and pharmacoeconomic models of Alzheimer's disease are being prepared by Pfizer and will be ready for the January launch of the product. Pfizer/Eisai's Aricept (donepezil, E2020) was approved on Nov. 25 for treatment of mild to moderate dementia of the Alzheimer's type. The cholinesterase inhibitor is the second drug approved for Alzheimer's. Warner-Lambert's cholinesterase inhibitor Cognex (tacrine) was approved in 1993 for the indication. Aricept will be competitively priced to Cognex, Pfizer said.